Skip to main content

Events & Outputs

Past Events

Wednesday
17
May

EViR Webinar on Animal-free Science

Members will have the opportunity to discuss what health funders (can) do to promote animal-free innovations and more human-relevant science, and how funders and regulators can engage as stakeholders to stimulate acceptance and implementation of animal-testing-free innovations.

This meeting is for EViR members only, please contact the secretariat if you would like to discuss your membership.

Presenting Organisations

  • Chair (MRH): Utrecht University, Faculty of Veterinary Medicine, Institute of Risk Assessment Sciences toxicology; co-chair preclinical working group EViR
  • ZonMw (BdW) – Dutch Health funding organisation; EViR board member; co-chair preclinical working group EViR
  • Swiss 3R foundation (HG) – 79NRP program = national research program for advancing the 3R alternatives to animal studies in Switzerland
  • European Medicines Agency (EMA) (SB) – EMA is responsible for the evaluation and approval of new drugs for the market

 3R = Replacement, Reduction and Refinement of animal studies

Agenda

  • Merel Ritskes-Hoitinga: Introduction
  • Sonja Beken: EMA and the 3R working party
  • Bas de Waard: ZonMw and funding of animal-testing free health science
  • Herwig Grimm: Swiss 3R funding programme
  • Merel and Bas: wrap up and closure

Speakers

  1. Sonja Beken – EMA evaluator for the non-clinical field; chair 3Rs working party chair; Belgium
  2. Bas de Waard – ZonMw coordinator of the program more knowledge with fewer animals; coordinator animal-free safety assessment funding calls; Netherlands
  3. Herwig Grimm – programme coordinator Swiss 3R foundation; Switzerland

Outcomes

  • What are funders already undertaking and what ways are there for funders to stimulate animal-free medical science through their procedures and requirements.
  • Exchange with funders on what can be done more in this field.
  • How can funders stimulate a more close interaction between researchers and regulators to enhance adoption of animal-free test methods.
  • How can the EMA 3R working party give input to funders and vice versa